Mediwound (M8W) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

M8W Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Mediwound

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

M8W Stock 12 Month Forecast

Average Price Target

€25.34

▲(72.40% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Mediwound in the last 3 months. The average price target is €25.34 with a high forecast of €31.46 and a low forecast of €19.23. The average price target represents a 72.40% change from the last price of €14.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","32":"€32","16.25":"€16.25","21.5":"€21.5","26.75":"€26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31.46055624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€31.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.343225859999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€25.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.22589548,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,16.25,21.5,26.75,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.6,14.050812018461539,15.501624036923076,16.952436055384617,18.403248073846154,19.85406009230769,21.30487211076923,22.75568412923077,24.206496147692306,25.657308166153847,27.108120184615387,28.55893220307692,30.00974422153846,{"y":31.46055624,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.6,13.580248143076922,14.560496286153846,15.540744429230768,16.52099257230769,17.501240715384615,18.48148885846154,19.46173700153846,20.441985144615384,21.422233287692308,22.402481430769228,23.38272957384615,24.362977716923076,{"y":25.343225859999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.6,13.109684267692307,13.619368535384615,14.129052803076922,14.63873707076923,15.148421338461537,15.658105606153846,16.167789873846154,16.67747414153846,17.18715840923077,17.696842676923076,18.206526944615383,18.71621121230769,{"y":19.22589548,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€31.46

Average Price Target€25.34

Lowest Price Target€19.23

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Okunewitch

Maxim Group

€26.22

Buy

78.35%

Upside

Reiterated

06/01/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Mediwound (NASDAQ: MDWD)

Swayampakula Ramakanth

H.C. Wainwright

€12.52→€31.46

Buy

114.02%

Upside

Reiterated

05/28/26

Ramakanth Reiterates Buy on MDWD, Citing Operational Trial Delay and Solid BARDA-Backed Outlook; $36 Price Target Unchanged

Jeff Jones

Oppenheimer

€29.71→€27.96

Buy

90.24%

Upside

Reiterated

05/28/26

Oppenheimer Sticks to Its Buy Rating for Mediwound (MDWD)

Scott Henry

Alliance Global Partners

€21.85→€19.23

Buy

30.79%

Upside

Reiterated

05/28/26

MediWound price target lowered to $22 from $25 at Alliance GlobalMediWound price target lowered to $22 from $25 at Alliance Global

Josh Jennings

TD Cowen

€21.85

Buy

48.62%

Upside

Reiterated

05/27/26

TD Cowen Keeps Their Buy Rating on Mediwound (MDWD)

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Simulations Plus (NASDAQ: SLP) and Mediwound (NASDAQ: MDWD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Okunewitch

Maxim Group

€26.22

Buy

78.35%

Upside

Reiterated

06/01/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Mediwound (NASDAQ: MDWD)

Swayampakula Ramakanth

H.C. Wainwright

€12.52→€31.46

Buy

114.02%

Upside

Reiterated

05/28/26

Ramakanth Reiterates Buy on MDWD, Citing Operational Trial Delay and Solid BARDA-Backed Outlook; $36 Price Target Unchanged

Jeff Jones

Oppenheimer

€29.71→€27.96

Buy

90.24%

Upside

Reiterated

05/28/26

Oppenheimer Sticks to Its Buy Rating for Mediwound (MDWD)

Scott Henry

Alliance Global Partners

€21.85→€19.23

Buy

30.79%

Upside

Reiterated

05/28/26

MediWound price target lowered to $22 from $25 at Alliance GlobalMediWound price target lowered to $22 from $25 at Alliance Global

Josh Jennings

TD Cowen

€21.85

Buy

48.62%

Upside

Reiterated

05/27/26

TD Cowen Keeps Their Buy Rating on Mediwound (MDWD)

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Simulations Plus (NASDAQ: SLP) and Mediwound (NASDAQ: MDWD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mediwound

3 Months

Michael OkunewitchMaxim Group

Success Rate

12/24 ratings generated profit

Average Return

+5.00%

Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +5.00% per trade.

1 Year

Michael OkunewitchMaxim Group

Success Rate

13/24 ratings generated profit

Average Return

+26.73%

Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +26.73% per trade.

2 Years

Michael OkunewitchMaxim Group

Success Rate

12/24 ratings generated profit

Average Return

+28.79%

Copying Michael Okunewitch's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +28.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

M8W Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, M8W has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. M8W average Analyst price target in the past 3 months is 25.34.

Each month's total comprises the sum of three months' worth of ratings.

M8W Financial Forecast

M8W Earnings Forecast

Next quarter’s earnings estimate for M8W is -€0.67 with a range of -€0.80 to -€0.60. The previous quarter’s EPS was -€0.20. M8W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year M8W has Performed in-line its overall industry.

M8W Sales Forecast

Next quarter’s sales forecast for M8W is €2.27M with a range of €1.95M to €2.72M. The previous quarter’s sales results were €1.29M. M8W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year M8W has Performed in-line its overall industry.

M8W Stock Forecast FAQ

What is DE:M8W’s average 12-month price target, according to analysts?

Based on analyst ratings, Mediwound’s 12-month average price target is 25.34.

What is DE:M8W’s upside potential, based on the analysts’ average price target?

Mediwound has 72.40% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Mediwound a Buy, Sell or Hold?

Mediwound has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mediwound’s share price target?

The average share price target for Mediwound is 25.34. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €31.46 ,and the lowest forecast is €19.23. The average share price target represents 72.40% Increase from the current price of €14.7.

What do analysts say about Mediwound?

Mediwound’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Mediwound?

To buy shares of DE:M8W, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Mediwound (M8W) Stock Forecast & Price Target

M8W Analyst Ratings

M8W Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mediwound

M8W Analyst Recommendation Trends

M8W Financial Forecast

M8W Earnings Forecast

M8W Sales Forecast

M8W Stock Forecast FAQ

Detailed List of Analyst Forecasts